8h
Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy
According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the ...
ADIA Nutrition Inc. (OTCQB: ADIA), today announced that its subsidiary, Adia Med of Winter Park, LLC., has officially begun ...
Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback